Compare AbbVie Inc (ABBV) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs DENTSPLY SIRONA Inc — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while DENTSPLY SIRONA Inc trades at $11.76 (market cap $2.44B). The key difference: AbbVie Inc is far larger — about 184.4× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals.
| ABBV | XRAY | |
|---|---|---|
Market Cap | $449.91B | $2.44B |
Sector | Health | Health |
52-Week High | $261.07 | $16.85 |
52-Week Low | $184.85 | $9.64 |
Enterprise Value | $513.38B | $4.58B |
Dividend Yield | 2.72% | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.65, down 0.04% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings expectations for three consecutive quarters, with Q2 2026 EPS expected at $3.79. Recent positive Phase 2 data for ELAHERE in ovarian cancer and strong institutional buying activity highlight growth momentum. Valuation metrics appear elevated with a P/E of 124.83 and P/B of 245.29, though the company maintains a robust gross margin of 70.68% and consistent dividend payments.
The outlook remains positive with analyst consensus at 'Buy' and a $266.33 price target, representing 4.6% upside. Key opportunities include Skyrizi and Rinvoq growth offsetting Humira declines, while risks include high debt levels, patent cliffs in the 2030s, and elevated valuation multiples that could pressure returns if growth slows.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
